Quality of Life Among Patients With Locally Advanced Pancreatic Cancer: A Prospective Nationwide Multicenter Study
Journal of the National Comprehensive Cancer Network · 2025
DOI: 10.6004/jnccn.2024.7091 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Journal of the National Comprehensive Cancer Network, 2025. Verfasst von Leonard W F Seelen und 24 weiteren Autor:innen. Beteiligte Einrichtung: 1Department of Surgery, University Medical Center Utrecht, St. Antonius Hospital Nieuwegein, Regional Academic Cancer Center Utrecht, Utrecht, the Ne…. Hauptthemen laut MEDLINE: Quality of Life, Pancreatic Neoplasms. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 54 Literaturangaben.
Abstract (Originalsprache)
Background
Health care providers of patients with cancer should discuss the impact of treatment, such as multiagent chemotherapy and surgery, on quality of life (QoL). However, in the era of shared decision-making, data on QoL in locally advanced pancreatic cancer (LAPC) remain scarce.
Methods
We performed a prospective multicenter study involving patients with LAPC across 13 Dutch centers. These patients were included in both the LAPC registry and the Dutch Pancreatic Cancer Project (PACAP; ClinicalTrials.gov identifier: NCT03513705 ). The study evaluated QoL over time and assessed the impact of treatment. The primary outcome was global health status (GHS) based on the EORTC Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30). Secondary outcomes included functioning and symptom scores from the EORTC QLQ-C30 and the EORTC QLQ Pancreatic Cancer Module (QLQ-PAN26). Outcomes were measured at diagnosis and at 3-month intervals up to 12 months. Outcomes were compared over time and between groups, with both statistical and clinical significance (Δ ≥10 points) evaluated.
Results
A total of 170 patients completed at least one QoL-questionnaire. Most patients (n=152; 89%) received tumor-directed treatment, including 116 (68%) who received chemotherapy (± radiotherapy) alone and 36 (21%) who underwent chemotherapy (± radiotherapy) followed by resection; 18 (11%) patients received best supportive care (BSC). At baseline, GHS was highest among patients who received chemotherapy + resection (mean [SD], 70 [16]) compared with those receiving chemotherapy alone (mean [SD], 64 [20]) and BSC (mean [SD], 48 [21]) ( P =.001). The overall mean [SD] GHS at baseline was 63 [20] and remained stable over time ( P =.27), including in patients receiving tumor-directed treatment ( P =.57). One-third of the QoL subscales (9/28) showed statistically and clinically significant changes over time. Improvements were observed in appetite loss, pancreatic pain, and hepatic symptoms, although patients reported increased diarrhea, flatulence, altered bowel habits, and financial difficulties. Over time, patients reported reduced fear of future health, but a decline in health care satisfaction.
Conclusions
This multicenter study demonstrated that general QoL remained stable during the first year in patients with LAPC, 89% of whom received tumor-directed treatment. Certain symptoms worsened and deserve greater attention from health care providers. These findings can guide shared decision-making and improve symptom management.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- 1Department of Surgery, University Medical Center Utrecht, St. Antonius Hospital Nieuwegein, Regional Academic Cancer Center Utrecht, Utrecht, the Netherlands.
- 2Department of Surgery, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands.
- 3Cancer Center Amsterdam, Amsterdam, the Netherlands.
- 4Division of Surgical Oncology, Department of Surgery, University of Colorado Anschutz Medical Campus, Aurora, Colorado.
- 5Department of Surgery, Maastricht University Medical Center, Maastricht, the Netherlands.
- 6Department of General, Visceral and Transplant Surgery, University Hospital Aachen, Aachen, Germany.
Zitieren
APA
Seelen, L. W. F., Augustinus, S., Stoop, T. F., Bouwense, S. A. W., Busch, O. R., Cirkel, G. A., van Eijck, C. H. J., de Vos-Geelen, J., Groot Koerkamp, B., Haj Mohammad, N., de Hingh, I. H. J. T., van Alphen, E., Homs, M. Y. V., Liem, M. S. L., Los, M., de Meijer, V. E., Mekenkamp, L. J. M., Sprangers, M. A. G., Stommel, M. W. J., …, & Dutch Pancreatic Cancer Group (2025). Quality of Life Among Patients With Locally Advanced Pancreatic Cancer: A Prospective Nationwide Multicenter Study. Journal of the National Comprehensive Cancer Network. https://doi.org/10.6004/jnccn.2024.7091
Vancouver
Seelen LWF, Augustinus S, Stoop TF, Bouwense SAW, Busch OR, Cirkel GA, et al. Quality of Life Among Patients With Locally Advanced Pancreatic Cancer: A Prospective Nationwide Multicenter Study. Journal of the National Comprehensive Cancer Network. 2025. doi:10.6004/jnccn.2024.7091
BibTeX
@article{Seelen2025,
author = {Seelen, Leonard W F and Augustinus, Simone and Stoop, Thomas F and Bouwense, Stefan A W and Busch, Olivier R and Cirkel, Geert A and van Eijck, Casper H J and de Vos-Geelen, Judith and Groot Koerkamp, Bas and Haj Mohammad, Nadia and de Hingh, Ignace H J T and van Alphen, Evelien and Homs, Marjolein Y V and Liem, Mike S L and Los, Maartje and de Meijer, Vincent E and Mekenkamp, Leonie J M and Sprangers, Mirjam A G and Stommel, Martijn W J and Wilmink, Johanna W and Besselink, Marc G and van Santvoort, Hjalmar C and van Laarhoven, Hanneke W M and Molenaar, I Quintus and Dutch Pancreatic Cancer Group, Dutch Pancreatic Cancer Group},
title = {Quality of Life Among Patients With Locally Advanced Pancreatic Cancer: A Prospective Nationwide Multicenter Study},
journal = {Journal of the National Comprehensive Cancer Network},
year = {2025},
doi = {10.6004/jnccn.2024.7091}
}
EUVIMED